May 8 |
IDEAYA Biosciences First Quarter 2024 Earnings: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)
|
May 7 |
IDEAYA Biosciences Inc (IDYA) Reports Q1 2024 Earnings: Financial and Strategic Developments
|
May 7 |
IDEAYA Biosciences GAAP EPS of -$0.53 misses by $0.01
|
May 7 |
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 1 |
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
|
Apr 24 |
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
|
Apr 22 |
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
|
Apr 5 |
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
Apr 1 |
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
|
Mar 27 |
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
|